Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous natural killer T cells
- Development stage
- Phase 1
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous natural killer T (NKT) cell therapy is an adoptive cell transfer biologic developed by the Peking University Cancer Hospital & Institute for the treatment of advanced melanoma. The therapy involves the ex vivo isolation and expansion of CD8+ NKT cells from a patient's peripheral blood mononuclear cells (PBMCs). This expansion is achieved using a specific cocktail of cytokines, including Interleukin-2 (IL-2), Interleukin-4 (IL-4), and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), along with the anti-CD3 monoclonal antibody OKT3. The resulting cell product consists of autologous CD8+ NKT cells, a unique lymphocyte population that expresses both T-cell receptors and natural killer cell markers. These cells are intravenously re-infused into the patient to exert anti-tumor effects through direct cytotoxicity and immune system modulation. A Phase I clinical trial (NCT02619058) demonstrated that the therapy is well-tolerated and shows preliminary efficacy in patients with metastatic melanoma.
- Other names
- NKT cellsautologous CD8+ NKT cellsCD8+ NKT cells
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on autologous natural killer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous natural killer T cells.